press-banner
press
Released date: April 27, 2016

Amyotrophic Lateral Sclerosis

PharmGPS® BYTES
Amyotrophic Lateral Sclerosis
ALS: A difficult fight to provide improved patient care amid dismal clinical development
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease characterized by the progressive degeneration of motor neuron circuitry, which includes neurons and Read More

press
Released date: April 20, 2016

Repurposing Drugs in Immuno-Oncology

PharmGPS® BYTES
Repurposing Drugs in Immuno-OncologyA Strategy in the Anti-Cancer Armamentarium
Drug repurposing as an attractive strategy in Immuno-Oncology drug development
The conventional process of introducing a new therapeutic to market, customarily takes more than a decade. The increasing cost Read More

press
Released date: April 14, 2016

OX40 Agonists: Promising Immuno-Oncology Therapies

PharmGPS® BYTES
OX40 Agonists: Promising Immuno-Oncology TherapiesA Strategy in the Anti-Cancer Armamentarium
The early promise of OX40 is being revived by the opportunity for combination
The rapid race to identify novel co-stimulatory agents to combine with approved checkpoint inhibitors is Read More

press
Released date: April 4, 2016

JAK and IL-6 Targeted Therapies in Rheumatoid Arthritis: The Challenge to the Old Guard

PharmGPS® BYTES
JAK and IL-6 Targeted Therapies in Rheumatoid ArthritisThe Challenge to the Old Guard
JAK and IL-6 Targeted Therapies in RA
Demonstrating superior efficacy in their respective pivotal trials against the current market leader, adalimumab, IL-6 and JAK inhibitor Read More